Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children aged ≥1 to <7 years with NF1-related Symptomatic, Inoperable PN

Trial Identifier: D1346C00004
Sponsor: AstraZeneca
Collaborator:
Merck Sharp & Dohme Corp.
Start Date: January 2022
Primary Completion Date: April 2024
Study Completion Date: April 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations